Payment overview · 2025
General Payments
$360.45
24 reported records · 6 companies
Healthcare provider profile · identity verified
Michael Aaron Workman, MD
Allopathic & Osteopathic Physicians|Family Medicine · HERRIN, IL · NPI 1184731267
Verified facts
What the public records show
CMS Open Payments records show Michael Aaron Workman, MD received $360.45 in general payments during 2025 across 24 reported records.
ABBVIE INC. accounted for 72.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 6 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ARMOUR THYROID as an associated drug or biological on 50 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Armour Thyroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Synthroid by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 86 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 216 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $261.58 | 72.6% | 18 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $24.16 | 6.7% | 2 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $23.87 | 6.6% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $20.09 | 5.6% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $17.06 | 4.7% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $13.69 | 3.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $360.45 | 24 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $261.58 | 18 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $24.16 | 2 | 2025 |
Source payment records
|
|||||
| TRINTELLIX Normalized: trintellix |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $23.87 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $20.09 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $20.09 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $13.69 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 86 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | ARMOUR THYROID open payments reported associated product |
CMS Open Payments — General Payments 50 supporting records · 11 recipient NPIs · example record 1201517088 |
Armour Thyroid · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
37 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
86 | 18 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
216 | 49 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
11 | 11 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 826 | 212 |
| Lisinopril | Lisinopril | 780 | 198 |
| Levothyroxine Sodium | Levothyroxine Sodium | 603 | 132 |
| Amlodipine Besylate | Amlodipine Besylate | 595 | 149 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 526 | 84 |
| Gabapentin | Gabapentin | 456 | 89 |
| Omeprazole | Omeprazole | 425 | 106 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 353 | 102 |
| Furosemide | Furosemide | 352 | 77 |
| Losartan Potassium | Losartan Potassium | 340 | 87 |
| Potassium Chloride | Potassium Chloride | 340 | 71 |
| Metoprolol Succinate | Metoprolol Succinate | 335 | 91 |
| Hydrochlorothiazide | Hydrochlorothiazide | 326 | 85 |
| Pantoprazole Sodium | Pantoprazole Sodium | 307 | 87 |
| Famotidine | Famotidine | 305 | 68 |
| Alprazolam | Alprazolam | 298 | 40 |
| Metformin Hcl | Metformin Hcl | 275 | 67 |
| Montelukast Sodium | Montelukast Sodium | 273 | 55 |
| Escitalopram Oxalate | Escitalopram Oxalate | 268 | 56 |
| Tamsulosin Hcl | Tamsulosin Hcl | 266 | 59 |
| Metoprolol Tartrate | Metoprolol Tartrate | 263 | 57 |
| Warfarin Sodium | Warfarin Sodium | 239 | 25 |
| Fluticasone Propionate | Fluticasone Propionate | 229 | 74 |
| Duloxetine Hcl | Duloxetine Hcl | 228 | 47 |
| Eliquis | Apixaban | 216 | 49 |
| Pravastatin Sodium | Pravastatin Sodium | 213 | 55 |
| Trazodone Hcl | Trazodone Hcl | 212 | 47 |
| Simvastatin | Simvastatin | 207 | 50 |
| Clopidogrel | Clopidogrel Bisulfate | 187 | 47 |
| Tramadol Hcl | Tramadol Hcl | 187 | 30 |
| Ezetimibe | Ezetimibe | 171 | 34 |
| Carvedilol | Carvedilol | 165 | 44 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 162 | 32 |
| Allopurinol | Allopurinol | 154 | 34 |
| Buspirone Hcl | Buspirone Hcl | 154 | 33 |
| Meloxicam | Meloxicam | 153 | 42 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 150 | 41 |
| Jardiance | Empagliflozin | 134 | 36 |
| Lorazepam | Lorazepam | 125 | 20 |
| Azelastine Hcl | Azelastine Hcl | 124 | 61 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 121 | 16 |
| Metformin Hcl Er | Metformin Hcl | 120 | 36 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 119 | 29 |
| Trulicity | Dulaglutide | 115 | 18 |
| Citalopram Hbr | Citalopram Hydrobromide | 110 | 21 |
| Clonazepam | Clonazepam | 104 | 16 |
| Prednisone | Prednisone | 104 | 63 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 102 | 13 |
| Sertraline Hcl | Sertraline Hcl | 94 | 18 |
| Ozempic | Semaglutide | 86 | 18 |
| Hydralazine Hcl | Hydralazine Hcl | 84 | 21 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 84 | 20 |
| Ventolin Hfa | Albuterol Sulfate | 79 | 20 |
| Glipizide | Glipizide | 77 | 17 |
| Diazepam | Diazepam | 72 | 17 |
| Methylprednisolone | Methylprednisolone | 70 | 66 |
| Ropinirole Hcl | Ropinirole Hcl | 70 | 16 |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 70 | 24 |
| Xarelto | Rivaroxaban | 70 | 15 |
| Donepezil Hcl | Donepezil Hcl | 69 | 16 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 68 | 22 |
| Spironolactone | Spironolactone | 68 | 14 |
| Atenolol | Atenolol | 67 | 18 |
| Lovastatin | Lovastatin | 66 | 20 |
| Mirtazapine | Mirtazapine | 63 | 13 |
| Cefuroxime | Cefuroxime Axetil | 62 | 47 |
| Pregabalin | Pregabalin | 62 | 13 |
| Farxiga | Dapagliflozin Propanediol | 61 | suppressed |
| Sucralfate | Sucralfate | 60 | 11 |
| Breo Ellipta | Fluticasone/Vilanterol | 58 | 13 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 58 | 15 |
| Ondansetron Hcl | Ondansetron Hcl | 58 | 18 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 55 | 20 |
| Tizanidine Hcl | Tizanidine Hcl | 55 | 12 |
| Bupropion Hcl Sr | Bupropion Hcl | 54 | 13 |
| Mounjaro | Tirzepatide | 53 | 12 |
| Nystatin | Nystatin | 52 | 20 |
| Paroxetine Hcl | Paroxetine Hcl | 52 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 52 | 12 |
| Dicyclomine Hcl | Dicyclomine Hcl | 50 | 12 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 50 | 13 |
| Glipizide Er | Glipizide | 49 | suppressed |
| Baclofen | Baclofen | 47 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 47 | 13 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 47 | suppressed |
| Hydrocortisone | Hydrocortisone | 45 | 31 |
| Glimepiride | Glimepiride | 44 | 11 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 43 | suppressed |
| Memantine Hcl | Memantine Hcl | 43 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 41 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 41 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 40 | 25 |
| Sumatriptan Succinate | Sumatriptan Succinate | 40 | suppressed |
| Levetiracetam | Levetiracetam | 39 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 38 | 16 |
| Temazepam | Temazepam | 38 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 37 | 30 |
| Ondansetron Odt | Ondansetron | 37 | 15 |
| Synthroid | Levothyroxine Sodium | 37 | suppressed |
| Januvia | Sitagliptin Phosphate | 36 | suppressed |
| Orphenadrine Citrate Er | Orphenadrine Citrate | 36 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 36 | 11 |
| Acyclovir | Acyclovir | 35 | 13 |
| Diclofenac Sodium | Diclofenac Sodium | 35 | 13 |
| Klor-Con M20 | Potassium Chloride | 35 | 13 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 35 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 34 | 11 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 33 | suppressed |
| Fluconazole | Fluconazole | 32 | 23 |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 31 | suppressed |
| Repatha Syringe | Evolocumab | 31 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 28 | suppressed |
| Telmisartan | Telmisartan | 27 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 26 | suppressed |
| Levofloxacin | Levofloxacin | 26 | 22 |
| Nitroglycerin | Nitroglycerin | 26 | 16 |
| Valacyclovir | Valacyclovir Hcl | 26 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 25 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 25 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 24 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 24 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 24 | suppressed |
| Nifedipine Er | Nifedipine | 24 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 24 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 24 | suppressed |
| Zaleplon | Zaleplon | 24 | suppressed |
| Bumetanide | Bumetanide | 23 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 23 | suppressed |
| Finasteride | Finasteride | 23 | suppressed |
| Ketoconazole | Ketoconazole | 23 | 11 |
| Primidone | Primidone | 23 | suppressed |
| Roflumilast | Roflumilast | 23 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 22 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 22 | suppressed |
| Estradiol | Estradiol | 22 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 22 | suppressed |
| Ramipril | Ramipril | 22 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 21 | suppressed |
| Bupropion Xl | Bupropion Hcl | 21 | suppressed |
| Entresto | Sacubitril/Valsartan | 21 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 21 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 21 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 21 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 21 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 20 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 20 | suppressed |
| Topiramate | Topiramate | 20 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 19 | suppressed |
| Ibuprofen | Ibuprofen | 19 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 18 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 18 | 14 |
| Benazepril Hcl | Benazepril Hcl | 18 | suppressed |
| Chlorthalidone | Chlorthalidone | 18 | suppressed |
| Torsemide | Torsemide | 18 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 17 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 17 | suppressed |
| Methimazole | Methimazole | 17 | suppressed |
| Novolog | Insulin Aspart | 17 | suppressed |
| Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 17 | suppressed |
| Aripiprazole | Aripiprazole | 16 | suppressed |
| Armour Thyroid | Thyroid,pork | 16 | suppressed |
| Carbamazepine | Carbamazepine | 16 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 16 | 13 |
| Diltiazem Hcl | Diltiazem Hcl | 16 | suppressed |
| Mupirocin | Mupirocin | 16 | 12 |
| Pioglitazone Hcl | Pioglitazone Hcl | 16 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 16 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 15 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 15 | suppressed |
| Methocarbamol | Methocarbamol | 15 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 15 | suppressed |
| Trueplus Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Clotrimazole | Clotrimazole | 14 | suppressed |
| Naproxen | Naproxen | 14 | suppressed |
| Novolog Flexpen | Insulin Aspart | 14 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 14 | suppressed |
| Admelog Solostar | Insulin Lispro | 13 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 13 | suppressed |
| Matzim La | Diltiazem Hcl | 13 | suppressed |
| Asenapine Maleate | Asenapine Maleate | 12 | suppressed |
| Cilostazol | Cilostazol | 12 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 12 | suppressed |
| Linzess | Linaclotide | 12 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 12 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 12 | suppressed |
| Risperidone | Risperidone | 12 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 12 | suppressed |
| Tradjenta | Linagliptin | 12 | suppressed |
| Valsartan | Valsartan | 12 | suppressed |
| Acetazolamide Er | Acetazolamide | 11 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 11 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 11 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 11 | 11 |
| Rasagiline Mesylate | Rasagiline Mesylate | 11 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $360.45 · 24 records | ABBVIE INC. | LEQVIO, Ozempic, Rybelsus, TRINTELLIX, VOQUEZNA, VRAYLAR | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error